Determinants of COVID-19 disease severity in patients with cancer

Robilotti, Elizabeth; Babady, N. Esther; Mead, Peter A.; Rolling, Thierry; Pérez-Johnston, Rocío; Bernardes, Marilia; Bogler, Yael; Caldararo, Mario; Figueroa, Cesar; Glickman, Michael S.; Joanow, Alexa; Kaltsas, Anna; Lee, Yeon Joo; Bianchi, Anabella Lucca; Mariano, A. T.; Morjaria, Sejal; Nawar, Tamara; Papanicolaou, Genovefa A.; Predmore, Jacqueline; Redelman-Sidi, Gil; Schmidt, Elizabeth K.; Seo, Susan K.; Sepkowitz, Kent A.; Shah, Monika K.; Wolchok, Jedd D.; Hohl, Tobias M.; Taur, Ying; Kamboj, Mini

doi:10.1038/s41591-020-0979-0

Cited by 543 publications

(656 citation statements)

References 22 publications

Supporting

Mentioning

602

Contrasting

Unclassified

Order By: Relevance

“…However, several lines of evidence suggest that suppressed immunity is not detrimental, but could be even beneficial for the anti-COVID-19 therapy. Immunosuppression and chemotherapy did not have a negative effect on severity of COVID-19 ( 41 , 42 ). Asymptomatic patients have lower levels of virus-specific antibody than those with severe disease manifestation ( 43 ).…”

Section: Discussionmentioning

confidence: 92%

Targeting Lipid Rafts—A Potential Therapy for COVID-19

et al. 2020

View full text Add to dashboard Cite

COVID-19 is a global pandemic currently in an acute phase of rapid expansion. While public health measures remain the most effective protection strategy at this stage, when the peak passes, it will leave in its wake important health problems. Historically, very few viruses have ever been eradicated. Instead, the virus may persist in communities causing recurrent local outbreaks of the acute infection as well as several chronic diseases that may arise from the presence of a “suppressed” virus or as a consequence of the initial exposure. An ideal solution would be an anti-viral medication that (i) targets multiple stages of the viral lifecycle, (ii) is insensitive to frequent changes of viral phenotype due to mutagenesis, (iii) has broad spectrum, (iv) is safe and (v) also targets co-morbidities of the infection. In this Perspective we discuss a therapeutic approach that owns these attributes, namely “lipid raft therapy.” Lipid raft therapy is an approach aimed at reducing the abundance and structural modifications of host lipid rafts or at targeted delivery of therapeutics to the rafts. Lipid rafts are the sites of the initial binding, activation, internalization and cell-to-cell transmission of SARS-CoV-2. They also are key regulators of immune and inflammatory responses, dysregulation of which is characteristic to COVID-19 infection. Lipid raft therapy was successful in targeting many viral infections and inflammatory disorders, and can potentially be highly effective for treatment of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 92%

Targeting Lipid Rafts—A Potential Therapy for COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…On the same note, blockade of the inhibitory receptors LAG-3 and TIM-3 as a therapeutic strategy in COVID-19 or malaria must be critically evaluated (69). On the one hand, it could enhance the effector T cell response to SARS-CoV-2 infection, on the other hand, such an intervention could also increase hyperinflammation.…”

Section: Discussionmentioning

confidence: 99%

Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease

et al. 2020

View full text Add to dashboard Cite

show abstract

“…After a full-text review, 23 articles were excluded due to the violation of inclusion criteria and the remaining 17 articles were eligible for inclusion in the current analysis. 3,13,15,16,[25][26][27][28][29][30][31][32][33][34][35][36][37]…”

Section: Discussionmentioning

confidence: 99%

“…3,13,15,16,[25][26][27][28][29][30][31][32][33][34][35][36][37] Detailed clinical characteristics of the study patients are reported in Table 1. Seven studies were performed in China, 3,9,13,15,25,26,32 five in the USA, 16,[27][28][29][30] two in Spain, 33,37 one in France, 36 and the other two in Italy. 31,35 Four of the included studies reported data on patients who diagnosis with COVID-19 while they received anti-cancer therapy.…”

Section: Study Characteristics and Quality Assessmentmentioning

confidence: 99%

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Wang

Huang

2020

OncoImmunology

View full text Add to dashboard Cite

Background: This study was designed to investigate whether COVID-19 patients with recently received immunotherapy or other anti-cancer treatments had more severe symptoms and higher mortality. Methods: A literature search was performed using the electronic platforms to obtain relevant research studies published up to June 28, 2020. Odds ratio (OR) and 95% confidence intervals (CI) of research endpoints in each study were calculated and merged. Statistical analyses were performed with Stata 12.0 (Stata Corp LP, College Station, TX). Results: A total of 17 studies comprising 3581 cancer patients with COVID-19 were included in this metaanalysis. SARS-CoV-2-infected cancer patients who recently received anti-cancer treatment did not observe a higher risk of exacerbation and mortality (All p-value >0.05). We also found that surgery, targeted therapy, chemotherapy, immunotherapy, and radiotherapy were not associated with increased risk of exacerbation and mortality (All p-value >0.05). Chemotherapy within 28 d increased the risk of death events (OR 1.45, 95% CI 1.10-1.91, P = .008, p-value = 0.015 for test of interaction), and immunotherapy within 90 d increased the risk of exacerbation (OR 2.53,95%1.30-4.91, P = .006, p-value = 0.170 for test of interaction). Conclusion: Cancer patients recently under anti-cancer treatment before diagnosed with COVID-19, including surgery, targeted therapy, immunotherapy, and radiotherapy, were not associated with increased risk of exacerbation and mortality. Chemotherapy within 28 d increased the risk of mortality, and chemotherapy was not associated with increased risk of severe COVID-19. The role of anti-cancer therapy in cancer patients with COVID-19 still needs further exploration, especially chemotherapy and immunotherapy.

show abstract

Determinants of COVID-19 disease severity in patients with cancer

Cited by 543 publications

References 22 publications

Targeting Lipid Rafts—A Potential Therapy for COVID-19

Targeting Lipid Rafts—A Potential Therapy for COVID-19

Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease

Immunotherapy or other anti-cancer treatments and risk of exacerbation and mortality in cancer patients with COVID-19: a systematic review and meta-analysis

Contact Info

Product

Resources

About